Amylyx Pharmaceuticals, Inc. (AMLX) - What Are Researchers Saying About This Stock?

Key Points

• Analyst sentiment is moderately bullish: Amylyx Pharmaceuticals has a “Moderate Buy” consensus from nine analysts, with seven buys, one strong buy, and one sell. The average 12-month price target is $40.71, with recent targets ranging from $39 to $55.
• Shares opened at $27.09 and have traded between $10.83 and $41.14 over the past year. The company reported a quarterly loss of $0.39 per share, missing the $0.36-loss consensus estimate.
• Institutional ownership is substantial at 95.84%: BlackRock and Jupiter Topco established large new positions, while insiders have sold 60,374 shares worth roughly $1.82 million over the past three months.

Shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Get Free Report) have received an average rating of "Moderate Buy" from the nine analysts that are covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, seven have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $40.71.

A number of equities research analysts have issued reports on AMLX shares. Robert W. Baird upped their price objective on shares of Amylyx Pharmaceuticals from $28.00 to $52.00 and gave the stock an "outperform" rating in a research report on Wednesday, August 19th. Mizuho lifted their target price on shares of Amylyx Pharmaceuticals from $30.00 to $42.00 and gave the stock an "outperform" rating in a research report on Tuesday, August 18th. Weiss Ratings reissued a "sell (d-)" rating on shares of Amylyx Pharmaceuticals in a research report on Wednesday, August 5th. HC Wainwright boosted their target price on Amylyx Pharmaceuticals from $34.00 to $55.00 and gave the stock a "buy" rating in a research note on Tuesday, August 18th. Finally, Citigroup upped their target price on Amylyx Pharmaceuticals from $32.00 to $39.00 and gave the company a "buy" rating in a report on Thursday, October 15th.

Amylyx Pharmaceuticals Stock Down 0.4%

Shares of NASDAQ:AMLX opened at $27.09 on Tuesday. Amylyx Pharmaceuticals has a twelve month low of $10.83 and a twelve month high of $41.14. The stock's 50 day moving average is $31.20 and its 200-day moving average is $19.64. The firm has a market capitalization of $3.02 billion, a price-to-earnings ratio of -18.94 and a beta of -0.10.

Amylyx Pharmaceuticals (NASDAQ:AMLX - Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.39) earnings per share for the quarter, missing analysts' consensus estimates of ($0.36) by ($0.03). Equities research analysts anticipate that Amylyx Pharmaceuticals will post -1.48 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, CFO James Frates sold 10,810 shares of Amylyx Pharmaceuticals stock in a transaction on Thursday, September 10th. The stock was sold at an average price of $32.36, for a total transaction of $349,811.60. Following the sale, the chief financial officer directly owned 233,625 shares in the company, valued at approximately $7,560,105. This trade represents a 4.42% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director M Jr sold 30,000 shares of the business's stock in a transaction on Monday, October 5th. The stock was sold at an average price of $27.70, for a total value of $831,000.00. Following the completion of the transaction, the director directly owned 782,881 shares in the company, valued at approximately $21,685,803.70. This represents a 3.69% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 60,374 shares of company stock valued at $1,815,257. 10.90% of the stock is owned by insiders.

Institutional Investors Weigh In On Amylyx Pharmaceuticals

A number of hedge funds have recently made changes to their positions in the business. BlackRock Inc. purchased a new position in shares of Amylyx Pharmaceuticals in the 2nd quarter worth about $158,534,000. Jupiter Topco LLC purchased a new stake in Amylyx Pharmaceuticals during the second quarter worth about $94,014,000. Janus Henderson Group PLC increased its holdings in Amylyx Pharmaceuticals by 11.6% during the first quarter. Janus Henderson Group PLC now owns 4,986,073 shares of the company's stock worth $69,257,000 after buying an additional 520,201 shares during the last quarter. Alyeska Investment Group L.P. purchased a new stake in Amylyx Pharmaceuticals during the second quarter worth about $18,912,000. Finally, Almitas Capital LLC purchased a new stake in Amylyx Pharmaceuticals during the second quarter worth about $17,509,000. 95.84% of the stock is currently owned by institutional investors.

About Amylyx Pharmaceuticals

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.